Cellectar Biosciences 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Cellectar Biosciences ended the 3rd quarter of 2026 with cash and cash equivalents of approximately $24.6 million, compared with $13.2 million as of December 31st, 2025.
- Research and development expenses for the 3 months ended September 30th, 2026 were approximately $5.4 million, compared with approximately $2.5 million for the same period in 2025; management attributed the increase mainly to the Phase 3 confirmatory trial and increased activity in the Phase 1B CLR-125 trial in triple-negative breast cancer.
- General and administrative expenses for the 3 months ended September 30th, 2026 were $2.7 million, compared with $2.3 million for the same period in 2025.
- Net loss for the 3 months ended September 30th, 2026 was $8.0 million, or $0.46 per share, compared with $4.4 million, or $1.41 per share, for the same period in 2025.
- Cellectar reported a major response rate of 79.2% and median duration of response of 16 months among patients treated immediately following BTK inhibitor therapy in a CLOVER-WM analysis presented in October.
- A separate subgroup analysis of CLOVER-WM patients treated with a BTK inhibitor immediately before iapofosin I-131 reported an overall response rate of 87.5%, major response rate of 79.2%, clinical benefit rate of 100%, and median duration of response of 16 months.
- The company reported a diffuse large B-cell lymphoma case in which a heavily pretreated patient achieved a complete response following a single administration of iapofosin I-131 in March of 2018 and remained in complete response more than 8 years later without additional anti-cancer therapy.
- Cellectar initiated a Phase 1b dosimetry study of iapofosin I-131 in patients with Waldenstrom's macroglobulinemia and continued enrollment in the Phase 1b CLR-125 trial in triple-negative breast cancer.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, ladies and gentlemen, and welcome to the Cellectar Biosciences Third Quarter Earnings Conference Call. At this time, all lines are in listen-only mode, and following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star 0 for the operator. This call is being recorded on Tuesday, November 10, 2026. I would now like to turn the conference call over to Ann-Marie Fields, Managing Director at Precision AQ. Please go ahead. Thank you.
Thank you, operator. Good morning, and welcome to Cellectar Biosciences Third Quarter 2026 Financial Results and Business Update Conference Call. Joining us today from Cellectar are Jim Caruso, President and CEO, who will provide an overview of the company's progress, before turning the call over to Chad Kolean, CFO, for a financial review of the quarter. Following this, Jarrod Longcor, Chief Operating Officer, will give an update on the company's progress and plans for its promising clinical development pipeline of radiopharmaceuticals. Cellectar issued a press release earlier this morning detailing the content of today's call. A copy can be found on the Investor page of Cellectar's corporate website. I want to remind callers that the information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be making forward-looking statements.
Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's press release and in our SEC filings. The content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, November 10, 2026. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call and webcast. As a reminder, this conference call and webcast are being recorded and archived. We will begin the call with prepared remarks, and then we will open the line for your questions. I will now turn the call over to Jim Caruso.
Jim? Thank you, Ann-Marie. Good morning, everyone, and thank you for joining us.
The third quarter was a highly productive and strategically important period for Cellectar Biosciences, as we continued to execute against what we believe is a defined path toward accelerated approval and potential commercialization of iopofosine I-131 for patients with relapsed or refractory Waldenström's macroglobulinemia, or WM. Over the last several quarters, we have systematically reduced risk across the clinical, regulatory, and operational components of our WM strategy. Today, we believe we are entering the most significant value-creating phase in our company's history as we advance towards several potentially transformational milestones, including the recent initiation of our confirmatory phase III study, advancement of our phase I-B dosimetry study, which includes the option to enroll first and second-line WM patients, and our planned NDA submission in the first half of 2027 seeking accelerated approval.
Most notably, we continue to make excellent progress with site activation and study startup activities for our confirmatory phase III trial and remain on track to dose the first patient in the first quarter of 2027. The initiation of patient dosing represents an important inflection point in our regulatory strategy, as it is expected to support a key requirement of our accelerated approval pathway. Importantly, we believe iopofosine I-131 could be approved and become commercially available as early as late 2027 or early 2028, positioning Cellectar to transition from a development-stage biotechnology company into a commercial-stage radiopharmaceutical company. We believe this opportunity represents a transformative milestone for the company and one of the most significant value drivers in our history. In parallel, we continue to strengthen the clinical foundation supporting the program.
Throughout 2026, we have generated and presented a growing body of evidence that we believe reinforces the differentiated profile of iopofosine I-131, including its potential to deliver durable responses in heavily pretreated patients with significant unmet medical need. In October, our team presented additional analysis from the CLOVER-WaM study at the International Workshop for Waldenström's Macroglobulinemia, demonstrating a major response rate of 79.2% and a median duration of response of 16 months in patients treated immediately following BTK inhibitor therapy. We believe these findings are particularly meaningful because they reflect the same patient population that will be evaluated in our confirmatory phase III trial and further support the clinical rationale for our accelerated approval strategy. Most recently, we announced three presentations at the upcoming American Society of Hematology Annual Meeting, or ASH, where we will continue expanding the growing body of evidence supporting iopofosine I-131 in WM.
These presentations include updated 12-month follow-up data from the CLOVER-WaM study. Analysis evaluating duration of response based on prior lines of therapy, and the first public presentation of our confirmatory phase III trial design. Collectively, these data continue to reinforce a highly consistent efficacy and safety profile while also suggesting that patients treated earlier in their disease course may experience a particularly durable benefit. As we continue to build this increasingly robust clinical package, our confidence in the potential of iopofosine I-131 and the strength of the overall opportunity continues to grow. Beyond WM, we are also seeing encouraging evidence supporting the broader applicability of iopofosine across hematologic malignancies. During the quarter, we presented a compelling case study involving a patient with diffuse large B-cell lymphoma who achieved a complete response following a single administration of iopofosine and maintained that response for more than eight years.
While this represents a single patient experience, it highlights the remarkable durability that may be achievable with targeted radiotherapeutic therapy and further underscores the broader potential of our technology. In addition to expanding the clinical evidence supporting iopofosine I-131, we also continued to showcase the scientific foundation underlying our platform. During the quarter, we hosted a successful educational webinar highlighting the unique biology of phospholipid ethers and the rationale behind our proprietary Phospholipid Drug Conjugate, or PDC, technology platform. We were very encouraged by the level of participation and engagement, which we believe reflects growing recognition of the platform's potential and its ability to move across multiple therapeutic opportunities. If you haven't listened in to the webinar or seen it, you can find it on the investors section of our website.
Importantly, the PDC platform serves as the foundation not only for iopofosine I-131, but also for our broader radiopharmaceutical pipeline. As we advance additional programs such as CLR 125, we are expanding a diversified portfolio of targeted radiotherapeutics that has the potential to create meaningful long-term value well beyond a single asset. Of course, I remain proud of the execution demonstrated by the entire Cellectar team throughout 2026. We have continued to advance key clinical and regulatory initiatives, expand the body of evidence supporting our lead program, strengthen the validation of our platform, and position the company for what we believe could be a transformational period ahead.
Supported by our balance sheet and the resources necessary to execute our strategy, we enter the final months of the year with significant momentum and a clear focus on delivering the milestones that we believe can create substantial value for both patients and shareholders. We look forward to reviewing our third quarter accomplishments in greater detail today and discussing the exciting opportunities that lie ahead. With that overview, I will now turn the call over to Chad for a review of our financial results.
Chad? Thank you, Jim, and good morning, everyone.
I will discuss our financial results for the period ended September 30, 2026. We ended the third quarter with cash and cash equivalents of approximately $24.6 million, compared to $13.2 million as of December 31, 2025. As previously reported, we successfully completed an oversubscribed financing of up to $140 million in early May, which is composed of an upfront payment of $35 million and $105 million in milestone-based capital. Our cash runway extends into the second quarter of 2027, which is sufficient to deliver important catalysts in our planned operations, including the initiation of our confirmatory phase III trial and potential new drug application submission. With respect to our results from operations, research and development expenses for the three months ended September 30, 2026, were approximately $5.4 million, compared to approximately $2.5 million for the three months ended September 30, 2025.
The overall year-over-year increase in R&D largely reflected costs associated with the initiation of the phase III confirmatory trial, as well as increased activity in the phase I-B CLR 125 trial in triple-negative breast cancer. General and administrative expenses for the three months ended September 30, 2026, were $2.7 million, compared to $2.3 million for the same period in 2025. The increase in G&A was primarily the result of increases in professional fees and personnel costs. Net loss for the three months ended September 30, 2026, was $8.0 million, or $0.46 per share, compared with $4.4 million, or $1.41 per share, during the three months ended September 30, 2025. We remain focused on our iopofosine I-131 program and strategic advancement toward multiple important milestones. I will now turn the call over to Jarrod for his comments on our regulatory and clinical advancements.
Thank you, Jim, and good morning, everyone. As Jim noted, Cellectar has entered a particularly important period in its evolution, where successful execution against key clinical, regulatory, and operational milestones has the potential to create substantial value for patients and shareholders alike. Our primary focus remains advancing iopofosine I-131 for accelerated approval in post-second line, post-exposure to BTKi and/or BTK inhibitor therapy in relapsed refractory Waldenström's macroglobulinemia, a patient population for which treatment options remain limited despite meaningful advances over the past decade. We have made significant progress establishing the operational foundation required to launch our global phase III confirmatory trial. Site activation activities are underway, and we remain on track to dose the first patient during the first quarter of 2027. Importantly, this study serves both a regulatory and commercial purpose.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
7 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
